Recent Advances in Near-Infrared Probes for Monitoring Drug Treatment Responses: Toward Efficacy Evaluation and High-Throughput Screening.
- 1School of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China.
- 2School of Civil and Architectural Engineering, Jiangxi University of Water Resources and Electric Power, Nanchang 330099, China.
Abstract
Accurate drug efficacy evaluation and efficient potential drug screening are cornerstones of translational pharmacology, as they can directly underpin the optimization of therapeutic regimens, acceleration of drug development pipelines, and improvement of patient clinical outcomes. However, conventional analytical approaches for these tasks often suffer from inherent limitations, including invasiveness, low sensitivity to subtle molecular changes, inability to achieve real-time in vivo monitoring of therapeutic dynamics, and poor compatibility with physiologically relevant disease models. In response to these unmet needs, near-infrared (NIR) fluorescent probes have emerged as transformative tools, leveraging a suite of unique advantages, such as noninvasiveness, ultrahigh sensitivity, excellent target specificity, operational simplicity, deep tissue penetration, and cost-effectiveness, to enable precise, spatiotemporal tracking of drug actions in both preclinical and early clinical settings. This review provides a comprehensive, up-to-date overview of recent advances in the rational design and translational applications of NIR probes for drug efficacy assessment and high-throughput screening (HTS). Specifically, NIR probes can systematically detect drug-induced biochemical and microenvironmental alterations and, when are integrated into automated HTS platforms, significantly enhancing screening sensitivity, throughput, and physiological relevance. Finally, we delineate key challenges impeding the widespread clinical translation of NIR probe technology and outline future research directions. Progress in therapeutic areas holds profound potential to refine personalized drug treatment strategies, accelerate late-stage clinical trial validation, and drive paradigm-shifting innovations across the global pharmaceutical industry.
Related
- Microscale high-throughput screening-assisted discovery of a photo/copper dual catalytic system for benzylic C(sp2)–C(sp3) Suzuki–Miyaura coupling: data mining and mechanistic insights
- Prediction of MOF Adsorption Isotherms and High-Throughput Screening Using a Physics-Informed Membranes Graph Neural Network
- A Fluorescence‐Based High‐Throughput Screening Method for EGFR Inhibitors Using an EGFR‐Targeted Environment‐Sensitive Fluorescent Probe
- Research on the Intervention of Bile Stasis-Induced Pruritus Using Small Molecules Targeting MRGPRX4 Through High-Throughput Screening
- Efficiency and Accessibility Are Not Enough: Chemical-Validity Filtering in High-Throughput Screening of Organic Photovoltaic Materials
BibTeX
@article{li2026recent,
title = {{Recent Advances in Near-Infrared Probes for Monitoring Drug Treatment Responses: Toward Efficacy Evaluation and High-Throughput Screening.}},
author = {Xinle Li and Shaobo Hou and Zhenghui He and Yi Sun and Yingxin Sun and Yalun Yao and Zi Long and Chong Duan and Jian-Liang Zhou},
journal = {Chemical \& biomedical imaging},
year = {2026},
month = may,
doi = {10.1021/cbmi.6c00055},
url = {https://europepmc.org/article/MED/42953287},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Recent Advances in Near-Infrared Probes for Monitoring Drug Treatment Responses: Toward Efficacy Evaluation and High-Throughput Screening.
AU - Xinle Li
AU - Shaobo Hou
AU - Zhenghui He
AU - Yi Sun
AU - Yingxin Sun
AU - Yalun Yao
AU - Zi Long
AU - Chong Duan
AU - Jian-Liang Zhou
PY - 2026
DA - 2026/05/18
JO - Chemical & biomedical imaging
DO - 10.1021/cbmi.6c00055
UR - https://europepmc.org/article/MED/42953287
AB - Accurate drug efficacy evaluation and efficient potential drug screening are cornerstones of translational pharmacology, as they can directly underpin the optimization of therapeutic regimens, acceleration of drug development pipelines, and improvement of patient clinical outcomes. However, conventional analytical approaches for these tasks often suffer from inherent limitations, including invasiveness, low sensitivity to subtle molecular changes, inability to achieve real-time in vivo monitoring of therapeutic dynamics, and poor compatibility with physiologically relevant disease models. In response to these unmet needs, near-infrared (NIR) fluorescent probes have emerged as transformative tools, leveraging a suite of unique advantages, such as noninvasiveness, ultrahigh sensitivity, excellent target specificity, operational simplicity, deep tissue penetration, and cost-effectiveness, to enable precise, spatiotemporal tracking of drug actions in both preclinical and early clinical settings. This review provides a comprehensive, up-to-date overview of recent advances in the rational design and translational applications of NIR probes for drug efficacy assessment and high-throughput screening (HTS). Specifically, NIR probes can systematically detect drug-induced biochemical and microenvironmental alterations and, when are integrated into automated HTS platforms, significantly enhancing screening sensitivity, throughput, and physiological relevance. Finally, we delineate key challenges impeding the widespread clinical translation of NIR probe technology and outline future research directions. Progress in therapeutic areas holds profound potential to refine personalized drug treatment strategies, accelerate late-stage clinical trial validation, and drive paradigm-shifting innovations across the global pharmaceutical industry.
SN - 2832-3637
ER -